OmniAb (OABI) Receivables (2021 - 2026)
OmniAb (OABI) posted quarterly Receivables of $16.1 million for Q1 2026, up 124.84% year-over-year from $7.2 million in Q1 2025, and up 97.06% quarter-over-quarter from $8.2 million in Q4 2025.
OmniAb (OABI) Receivables (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Receivables for 6 consecutive years, with $16.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 124.84% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (up 124.84% YoY), while the FY2025 annual figure was $8.2 million, up 4.04% from the prior year.
- Receivables rose to $16.1 million in Q1 2026 per OABI's latest filing, from $8.2 million in the prior quarter.
- Across five years, Receivables topped out at $30.3 million in Q4 2022 and bottomed at $1.8 million in Q1 2023.
- Historically, Receivables has averaged $8.0 million across 5 years, with a median of $6.5 million in 2023.
- Annual changes were most pronounced in 2023 — Receivables sank 84.67% — and 2026, when it surged 124.84%.
- OmniAb's Receivables stood at $30.3 million in 2022, then tumbled by 84.67% to $4.6 million in 2023, then jumped by 69.51% to $7.9 million in 2024, then grew by 4.04% to $8.2 million in 2025, then soared by 97.06% to $16.1 million in 2026.
- Business Quant data shows OABI's Receivables at $16.1 million in Q1 2026, $8.2 million in Q4 2025, and $3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 11.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.23 Mn |
| Mar 31, 2026 | 16.14 Mn |
| Dec 31, 2025 | 8.19 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 3.11 Mn |
| Mar 31, 2025 | 7.18 Mn |
| Dec 31, 2024 | 7.87 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | 6.88 Mn |
| Mar 31, 2024 | 4.05 Mn |
| Dec 31, 2023 | 4.64 Mn |
| Sep 30, 2023 | 6.14 Mn |
| Jun 30, 2023 | 8.61 Mn |
| Mar 31, 2023 | 1.82 Mn |
| Dec 31, 2022 | 30.29 Mn |
| Dec 31, 2021 | 21.14 Mn |